Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma

Chinese Journal of Pathology

Volumn 41, Issue 12, 2012, Pages 818-822

  Yao, Wei Kai ^a   Wang, Yin Ping ^a   Peng, Fang ^a   Zheng, Yan ^a   Zou, Ya Bin ^a   Gao, Jing Na ^a   Liu, Xue Li ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

B cell diffuse; Lymphoma large; Lymphoma non hodgkin; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENT COMPONENT C3D RECEPTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; TUMOR MARKER; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CHILD; FEMALE; GASTROINTESTINAL TUMOR; GERMINAL CENTER; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GASTROINTESTINAL NEOPLASMS; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; L-LACTATE DEHYDROGENASE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; RECEPTORS, COMPLEMENT 3D; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; YOUNG ADULT;

EID: 84872434441     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2012.12.006     Document Type: Article

References (13)

1. Rossi D, Gaidano C. Molecular heterogeneity of diffuse large B-eell lymphoma; implications for disease management and prognosis. Hematology, 2002, 7(4):239-252. (Pubitemid 35390324)
2. Tomita N, Kodama F, Motomura S, et al. Prognostic factors in diffuse large B-cell lymphoma treated by risk-adopted therapy. Intern Med, 2006, 45(5):247-252.
3. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103(1):275-282. (Pubitemid 38029949)
4. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res, 2009, 15(17):5494-5502.
5. Otsuka M, Yakushijin Y, Hamada M, et al. Role of CD21 antigen in diffuse large B-cell lymphoma and its clinical significance. Br J Haematol, 2004, 127(4):416424.
6. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403(6769):503-511. (Pubitemid 30082188)
7. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103(1):275-582.
8. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood, 2002, 99(4):1136-1143. (Pubitemid 34547064)
9. Fearon DT. The CD19-CR2-TAPA-1 complex, CD45 and signaling by the antigen receptor of B lymphocytes. Curr Opin Immunol, 1993, 5(3):341-348. (Pubitemid 23197444)
10. Cherukuri A, Cheng PC, Sohn HW, et al. The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity, 2001, 14(2):169-179. (Pubitemid 32206519)
11. Barel M, Le Romancer M, Frade R. Activation of the EBV/C3d receptor (CR2, CD2I) on human B lymphocyte surface triggers tyrosine phosphorylation of the 95-kDa nucleolin and its interaction with phosphatidylinositol 3 kinase. J Immunol, 2001, 166(5):3167-3173. (Pubitemid 33117314)
12. Fresno Vara JA, Casado E, De Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev, 2004, 30(2):193-204.
13. Tanimoto K, Yakushijin Y, Fujiwara H, et al. Clinical significance of co-expression of CD21 and LFA-1 in B-cell lymphoma. Int J Hematol, 2009, 89(4):497-507.